WO2008152462A1 - A process of sulfoxidation of biologically active compounds - Google Patents
A process of sulfoxidation of biologically active compounds Download PDFInfo
- Publication number
- WO2008152462A1 WO2008152462A1 PCT/IB2008/001423 IB2008001423W WO2008152462A1 WO 2008152462 A1 WO2008152462 A1 WO 2008152462A1 IB 2008001423 W IB2008001423 W IB 2008001423W WO 2008152462 A1 WO2008152462 A1 WO 2008152462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- och
- solvent
- base
- formula
- added
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B45/00—Formation or introduction of functional groups containing sulfur
- C07B45/04—Formation or introduction of functional groups containing sulfur of sulfonyl or sulfinyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to an improved process for the preparation of sulfoxides and more particularly the invention provides stereoselective preparation of substituted or unsubstituted chiral sulf ⁇ nyl derivates of general formula (I) by oxidation with oxaziridine 10 in presence of suitable solvent and base.
- the sulfone impurity is formed during the sulfide to sulfoxide conversion due to over oxidation is alarming.
- the sulfone impurity is mainly due to over oxidation, which inturn is related to oxidizing agents. The oxidation thus needs to be controlled.
- US 5,929,244 discloses a method for the preparation of esomeprazole by utilizing (3'S, 2R)-(-)-N-(phenylsulphonyl)-(3, 3-dichlorocamphoryl) oxaziridine in the presence of triethyl amine as a base and carbon tetrachloride as solvent.
- the optical purity is 94%, but however, the yield obtained is only 22%, thereby making the process unfeasible for commercial use. This is also compounded by the use of carbon tetrachloride as a solvent, which is banned on industrial scale.
- the reagent used for chiral induction is diethyl-tartarate which is difficult to recover due to epimerization and hydrolysis during workup.
- the reagent used for oxidation is cumene hydroperoxide, which is explosive and hazardous, apart from being costly.
- Tetrahedron Asymmetry 1995, 6(12), 291 1-2914 discloses a method for the oxidation of sulfides to sulfoxides utilizing [(3,3-dimethoxycamphoryl) sulfonyl]oxaziridine (IV) in the presence of hydrogen peroxide. Utilization of this oxaziridine gives sulfoxides from non- aryl sulfides with good enantioselectivity.
- the method relates to oxidation of a sulfide group, which is flanked by either an aryl or alkyl group on one side or an alkyl group on the other side.
- a sulfide group which is flanked by either an aryl or alkyl group on one side or an alkyl group on the other side.
- Tetrahedron Asymmetry 2003, 14, 407-410 teaches a method for the preparation of (R)- lansoprazole by utilizing a heterogenous catalytic system Of WO 3 , 30% H 2 O 2 and cinchona alkaloids.
- Industrial use of such a system is quite restricted due to the use of costly reagents like WO 3 and cinchona alkaloids. Further restriction is also due to hazards of H 2 O 2 .
- Ternois James et. al. disclose a method for the enantioselective oxidation of the sulfide group to sulfoxide using an oxaziridine of formula (V) for preparation of certain pharmaceutical compounds.
- the method either utilizes carbon tetrachloride, ionic liquids and the reaction time is about 48 hours reducing the efficiency of the process.
- carbon tetrachloride has several adverse health effects, like carbon tetrachloride is a carcinogenic solvent, ozone depleting agent. Chronic exposure of carbon tetrachloride can affect the central nervous system, cause liver and kidney damage and could result in cancer. Further the use of ionic liquid like l-butyl-3-methylimidazolium hexafluorophosphate, which are known to be non-volatile, pose grave problems during drying of active pharmaceutical ingredients.
- ionic liquids can be used as solvent for their preparation, due to their non-volatility; also, these ionic liquids require the use of an ultrasonic device to degrade solutions of imidazolium-based ionic liquids with hydrogen peroxide and acetic acid to relatively innocuous compounds. Furthermore, the enantiomeric excess obtained by using oxaziridine reagent is upto 78%, which is insufficient.
- the method requires low temperature of around -7O 0 C and provides only 60% conversion of the sulfide intermediate to the desired product. Due to the stringent temperature conditions and low product conversion, apart from the drawbacks of the oxidizing agents, this method is not suitable for industrial purpose.
- An object of the present invention is to provide an improved, simple, cost effective and environment friendly process for the stereoselective preparation of substituted or unsubstituted chiral sulfinyl derivates of general formula (I) with good yield and high enantiomeric purity.
- the present invention relates to an improved, simple, cost effective and environment friendly process for the stereoselective preparation of substituted or unsubstituted chiral sulfinyl derivates with less sulfone impurity and high enantiomeric purity by oxidation with oxaziridine in presence of suitable solvent and base.
- the present invention provides a process for preparing the compound of formula (I) comprising the steps of reacting the compound of formula (Ia) with an oxaziridine of formula (VII) in presence of a solvent and a base and isolating a compound of formula (I) as required for pharmaceutical substances.
- one of the enantiomers may be obtained in enantiomeric excess over the other.
- compound of formula (I) may be selected from the group comprising optically active prazoles such as pantoprazole, lansoprazole, rabeprazole, tenatoprazole, pariprazole and omeprazole or the compound as disclosed in US 5,776,765.
- compound of formula (I) may be armodafinil as disclosed in US 4,927,855.
- Modafinil has a stereogenic center at the sulphur atom and thus exists as two optical isomers i.e. enantiomers.
- the R enantiomer of modaf ⁇ nil which is the preferential enantiomers is known as armodafinil and has chemical name 2-[(R)-(diphenylmethyl) sulfinyl] acetamide.thus, the process of the invention may be used for the preparation of any racemic sulfoxide, examples of which have been disclosed above.
- racemic oxaziridines For obtaining the racemic sulfoxides, the racemic oxaziridines may be used.
- the oxidizing agent used is compound of formula (VIII)
- R 6 , R 7 and Rg are chiral moieties having chiral center.
- the oxidizing agent used in the present invention is dextrorotatory or levorotatory isomers of the (2R, 8aS)-10-(Camphoryl sulfonyl) oxaziridine as depicted in formula (VII).
- the (+) enantiomer i.e. (+)-(2R,8aS)-10- (camphorsulfonyl) oxaziridine is used to get the respective enantiomer of sulfoxide.
- the (- ) isomer of the same compound can also be used for obtaining the enantiomerically enriched compound.
- the chiral oxidizing agent used according to the process is chiral oxaziridine, which can be obtained without use of metal complexes such as titanium tetra isopropoxide. Titanium tetraisopropoxide is the enormous load on effluent treatment plant and hence it is not environment friendly.
- the reaction of the present invention is carried in the presence of organic or inorganic base.
- the inorganic base is selected from the group comprising of hydroxides, alkoxides, and bicarbonates, carbonates of alkali or alkaline earth metals and preferred inorganic base is sodium hydroxide or potassium hydroxide.
- the preferred base is an organic base.
- the organic base used is selected from the group comprising of 1,8-diazabicyclo [5.4.0] undec-7-ene, diisopropyl ethyl amine, hexamethylene tetra amine, triethyl amine and alike.
- the preferred base utilized for the oxidation is 1,8-diazabicyclo [5.4.0] undec-7-ene.
- the solvent used for the present invention is selected from the group of organic solvents comprising of alcohols, ethers, esters, amides, nitriles, aromatic hydrocarbons, water etc. or combinations thereof.
- the preferred solvents are selected from the group comprising of methanol, ethanol, isopropanol, butanol, diisopropyl ether, toluene, water, tetrahydrofuran, acetonitrile, dimethylformamide, diethylformamide, dimethoxyethane or combinations thereof etc.
- the solvent does not cover ionic solvents.
- the reaction of the formation of the sulfoxide is carried out at room temperature.
- Example 1 In 250 ml. flask, 10 gm of Rabeprazole sulfide was suspended in 70 ml isopropylalcohol. To it 4.4 gm 1 ,8-Diazabicyclo [5.4.0] undec-7-ene was added and cooled to 10 to 15 0 C. Further, 6.6 gm (+)-(2R, 8aS)-10-(Camphoryl sulfonyl) oxaziridine was added and stirred till the sulfide is reacted (for about 20 hrs) at 25 to 30 0 C. The reaction mixture was filtered and solid was washed with isopropyl alcohol to get 5.1 gm (-)-(Camphorsulfonyl) imine (Recovery 78%).
- Enantiomeric purity of any single isomer for example R-isomer can be further enriched by converting R-Rabeprazole into R-Rabeprazole sodium and / or by dissolving R- Rabeprazole sodium in water and adjusting the pH with acetic acid.
- (+)-(2R, 8aS)-10-(Camphorylsulfonyl) oxaziridine was added and stirred till at 25 to 30 0 C till the reaction goes to completion.
- the reaction mixture was filtered and solid was washed with water to get chirally pure 8 gm Armodafinic acid.
- Rabeprazole sulfide (lgm, 0.0029 moles) was ' added to Isopropyl alcohol (7ml) in a 100ml flask. The flask was cooled to 15 to 2O 0 C, 1,8-Diazabicyclo [5.4.0] undec-7-ene (0.44gms, 0.0029moles) was added and stirred for 10 min. Reaction mass was further cooled to 10 to 15 0 C and diisopropyl ether (3ml) was charged along with (+)-(2R,8aS)-10- (Camphorylsulfonyl) oxaziridine (0.66gms, 0.0029moles) at 10 to 15 0 C.
- Rabeprazole sulfide (l gm, 0.0029 mole) was added to water (7ml) in a flask and cooled to 15 to 2O 0 C. 1 ,8-Diazabicyclo [5.4.0] undec-7-ene (0.44gms, 0.0029moles) was added and stirred for 5 minutes. Reaction mass was further cooled to 10 to 15 0 C and (+)-(2R,8aS)- 10-(Camphorylsulfonyl) oxaziridine (0.66gms, 0.0029moles) was added. Reaction mass was stirred for 30min and stirred further at 25 to 3O 0 C, till completion of reaction as monitored by HPLC. Chemical Purity: 62.54% R-Isomer: 70.45%. S-Isomer: 29.54%.
- Rabeprazole sulfide (lgm, 0.0029 mole) was added to dimethyl formamide (7ml) in a flask and cooled to 15 to 2O 0 C. 1,8-Diazabicyclo [5.4.0] undec-7-ene (0.44gms,
- Pantoprazole sulfide (lgm, 0.0027 moles) was added to dichloromethane (7ml) into a flask and cooled to 15 to 2O 0 C. 1,8-Diazabicyclo [5.4.0] undec-7-ene (0.41gms, 0.0027moles) was added and stirred for 10 minutes. Reaction mixture was further cooled to 10 to 15 0 C and (+)-(2R,8aS)-10-(Camphorylsulfonyl) oxaziridine (0.63gms, 0.0027moles) was added.
- reaction mixture was stirred for 30 minutes at 10 to 15 0 C and then stirred further at 25 to 3O 0 C.
- the reaction mixture was monitored by HPLC, till completion of reaction and then quenched with aqueous sodium hydroxide and extracted with MDC. The organic layer was separated and concentrated to get the product.
- Example 7 (S-Pantoprazole: diisopropylethylamine as base and methanol as solvent) Pantoprazole sulfide (l gms, 0.0027 moles) was added to methanol (7ml) in a 100ml flask and cooled to 15 to 2O 0 C. Diisopropyl ethyl amine (0.35gms, 0.0027moles) was added and stirred for 10 minutes.
- reaction mixture was further cooled to 10 to 15 0 C and (+)- (2R,8aS)-10-(Camphoryl sulfonyl) oxaziridine (0.63gms, 0.0027moles) was added.
- Reaction mixture was agitated at 25 to 3O 0 C, till the completion of reaction by TLC.
- the reaction mixture was quenched with dilute sodium hydroxide and extracted with dichloromethane. The organic layer was separated and concentrated. Chemical Purity: 98.24% R-Isomer: 74.67%. S-Isomer: 25.33%.
- Example 8 Purprazole using an inorganic base in an organic solvent
- Pantoprazole sulfide (lgm; 0.0027 moles) was added to methanol (4ml) in a 100ml flask. Flask was cooled to 15 to 2O 0 C, and sodium hydroxide solution (0.108gms, 0.0027moles) was added and stirred at 10 to 15 0 C and (+)-(2R,8aS)-10-Camphorylsulfonyl oxaziridine (0.63gms,0.0027moles) (0.63gms, 0.0027moles) was charged.
- Rabeprazole sulfide (40gms, 0.116 moles) was added to isopropyl alcohol (7ml) in a 100ml flask and cooled to 15 to 2O 0 C.
- 1,8-Diazabicyclo [5.4.0] undec-7-ene (17.9gms, O.l l ⁇ moles) was added and stirred at 10 to 15 0 C.
- (+)-(2R, 8aS)-10-camphoryl sulphonyl oxaziridine (25.3gms, 0.1 lOmoles) was charged. Reaction mass was stirred at 25 to 3O 0 C, till the completion of reaction. The reaction mass was filtered and the filtrate was concentrated under reduced pressure.
- Example 10 (Reaction for any prazole in any solvent without an inorganic or organic base in any solvent)
- Rabeprazole sulfide (lgm, 0.0029 moles) was added to Isopropyl alcohol (7ml) in a 100 ml flask and cooled to 10 to 15 0 C.
- (+)-(2R,8aS)-10-camphoryl sulphonyl oxaziridine (0.66gms, 0.0029moles) was added and the reaction mixture stirred at 25 to 3O 0 C, till the completion of reaction as monitored by TLC and HPLC,.
- Sodium hydroxide solution was added to the reaction mixture followed by dichloromethane (5ml). The organic layer was separated and concentrated to obtain the product.
- the filtrate was cooled to 15 to 2O 0 C and the pH adjusted with acetic acid around pH 7.5.
- the reaction mass was stirred for 2 hours at 15 to 2O 0 C and the solid separating out was filtered.
- the wet cake was suspended in water (3735ml).
- Sodium hydroxide solution (55.2gms in 415ml of water) was added to the flask and stirred for 30 minutes.
- the solid obtained was filtered; the filtrate was extracted with dichloromethane (830ml).
- the aqueous layer was separated and the pH adjusted to 7.45 with 50% acetic acid solution.
- the aqueous layer was separated and extracted with dichloromethane (830ml).
- Omeprazole sulfide (50gms; 0.152 moles) was added to isopropyl alcohol (350ml). 1,8- Diazabicyclo [5.4.0] undec-7-ene (23.1 gms; 0.152 moles) was added to the mixture at 10- 15 0 C. l(R)-(-)-(Camphorylsulfonyl)oxaziridine (34.8gms; 0.151moles) was added to the mixture and allowed to stir for 20 hours till completion of reaction as monitored on TLC. The reaction was filtered and the filtrate concentrated at reduced pressure. Water (250ml) was added to the residue and the pH adjusted around 8.5 with acetic acid.
- Esomeprazole sodium (5.0gms; 0.1636moles) was dissolved in water (30ml) and added dropwise to a solution of magnesium chloride (0.54gms; 0.0068moles) in water (30ml) at room temperature. The resultant mixture was stirred for 1 hour and filtered. The wet cake was washed with water (30ml) and dried. Yield: 4.87 gms.
- Pantoprazole sulfide 400gms; 1.089moles was added to isopropyl alcohol (3600ml). 1,8- Diazabicyclo [5.4.0] undec-7-ene (164gms) was added to the mixture and cooled to 10- 15°C.
- (R)-(-)-Camphorylsulphonyl)oxaziridine (259.70gms; 1.133moles) was added and the temperature raised to 25-3O 0 C and stirred till completion of reaction by HPLC. The reaction mixture was filtered and the filtrate partially concentrated under reduced pressure. Water (2000ml) was added to the residue and filtered.
- the pH of the filtrate was adjusted to 9.5 with acetic acid and diluted with ethyl acetate (2000ml). The pH was further adjusted around 7.5 with acetic acid and separated the organic layer, which was then concentrated partially and diluted with cyclohexane. The mixture was cooled to 10-15 0 C and the product separating out was filtered. The wet cake was added to ethyl acetate (2800ml), warmed to 7O 0 C and partially concentrated under reduced pressure. The residue was diluted with cyclohexane (400ml) and the product separating out was filtered at 10- 15 0 C. Yield: 243gms % Yield: 60%. Chemical Purity: 99.95%. Optical Purity: 98.62%.
- the advantages of the present invention are as under: A. Cost effective and industrially feasible process. B. Makes use of an oxidizing agent which can easily recover.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0813191-0A BRPI0813191B1 (en) | 2007-06-15 | 2008-06-04 | SULFOXIDATION PROCESS OF BIOLOGICALLY ACTIVE COMPOUNDS |
KR1020107000731A KR101432866B1 (en) | 2007-06-15 | 2008-06-04 | A process of sulfoxidation of biologically active compounds |
EA201070021A EA016297B1 (en) | 2007-06-15 | 2008-06-04 | A process of sulfoxidation of biologically active compounds |
ZA2009/08887A ZA200908887B (en) | 2007-06-15 | 2009-12-14 | A process of sulfoxidation of biologically active compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1124/MUM/2007 | 2007-06-15 | ||
IN1124MU2007 | 2007-06-15 | ||
IN35/MUM/2008 | 2008-01-07 | ||
IN35MU2008 | 2008-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008152462A1 true WO2008152462A1 (en) | 2008-12-18 |
Family
ID=39790870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/001423 WO2008152462A1 (en) | 2007-06-15 | 2008-06-04 | A process of sulfoxidation of biologically active compounds |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR101432866B1 (en) |
BR (1) | BRPI0813191B1 (en) |
EA (1) | EA016297B1 (en) |
WO (1) | WO2008152462A1 (en) |
ZA (1) | ZA200908887B (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009024863A2 (en) * | 2007-06-26 | 2009-02-26 | Actavis Group Ptc Ehf | Process for the preparation of modafinil enantiomers |
CN102329302A (en) * | 2011-10-22 | 2012-01-25 | 刘强 | Method for preparing esomeprazole and salts thereof |
CN102432412A (en) * | 2011-10-28 | 2012-05-02 | 成都欣捷高新技术开发有限公司 | Preparation method of chiral sulphoxide proton pump inhibitor or pharmaceutically-acceptable salt thereof |
CN102603621A (en) * | 2012-02-07 | 2012-07-25 | 成都苑东药业有限公司 | Novel chiral sulfoxide compound and method for preparing esomeprazole by using novel chiral sulfoxide compound |
CN102924434A (en) * | 2012-10-18 | 2013-02-13 | 江苏诚信制药有限公司 | Dexrabeprazole sodium monohydrate crystal form and preparation method thereof |
CN103113350A (en) * | 2013-02-27 | 2013-05-22 | 安徽省新星药物开发有限责任公司 | Novel crystal form of R-rabeprazole sodium hydrate, preparation method and application thereof |
JP2013519655A (en) * | 2010-02-12 | 2013-05-30 | エステヴェ キミカ, エス.エー. | Preparation method of sodium salt of esomeprazole sodium |
WO2013104605A3 (en) * | 2012-01-10 | 2013-09-26 | Studiengesellschaft Kohle Mbh | Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst |
CN103772355A (en) * | 2012-10-25 | 2014-05-07 | 天津汉瑞药业有限公司 | Rabeprazole sodium compound |
CN104327049A (en) * | 2014-09-27 | 2015-02-04 | 湖南五洲通药业有限责任公司 | Preparation method of right-handed rabeprazole sodium monohydrate crystal |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5929244A (en) * | 1995-07-03 | 1999-07-27 | Astra Aktiebolag | Process for the optical purification of enantiomerically enriched benzimidazole derivatives |
US6919459B2 (en) * | 2001-07-16 | 2005-07-19 | Rudy Laurent Maria Broeckx | Process for preparing benzimidazole-type compounds |
-
2008
- 2008-06-04 KR KR1020107000731A patent/KR101432866B1/en active IP Right Grant
- 2008-06-04 WO PCT/IB2008/001423 patent/WO2008152462A1/en active Application Filing
- 2008-06-04 BR BRPI0813191-0A patent/BRPI0813191B1/en active IP Right Grant
- 2008-06-04 EA EA201070021A patent/EA016297B1/en unknown
-
2009
- 2009-12-14 ZA ZA2009/08887A patent/ZA200908887B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5929244A (en) * | 1995-07-03 | 1999-07-27 | Astra Aktiebolag | Process for the optical purification of enantiomerically enriched benzimidazole derivatives |
US6919459B2 (en) * | 2001-07-16 | 2005-07-19 | Rudy Laurent Maria Broeckx | Process for preparing benzimidazole-type compounds |
Non-Patent Citations (3)
Title |
---|
FRANKLIN A DAVIS ET AL: "Chemistry of Oxaziridines.17. N-(Phenylsulfonyl)(3,3-dichlorocamphoryl)oxaziridine: A Highly Efficient Reagent for the Asymmetric Oxidation of Sulfides to Sulfoxides", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 114, 1992, pages 1428 - 1437, XP002499828 * |
GUDRUN GLAHSL ET AL: "(+)-(3-Oxocamphorsulphonyl)oxaziridine as a Highly Stereoselective Reagent for the Oxidation of Sulphides to Chiral Sulphoxides", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, 1988, pages 1753 - 1757, XP002499829 * |
TERNOIS ET AL: "Asymmetric synthesis of modafinil and its derivatives by enantioselective oxidation of thioethers: comparison of various methods including synthesis in ionic liquids", TETRAHEDRON ASYMMETRY, PERGAMON, OXFORD; GB, vol. 18, no. 24, 21 December 2007 (2007-12-21), pages 2959 - 2964, XP022400759, ISSN: 0957-4166 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009024863A3 (en) * | 2007-06-26 | 2009-08-06 | Actavis Group Ptc Ehf | Process for the preparation of modafinil enantiomers |
WO2009024863A2 (en) * | 2007-06-26 | 2009-02-26 | Actavis Group Ptc Ehf | Process for the preparation of modafinil enantiomers |
JP2013519655A (en) * | 2010-02-12 | 2013-05-30 | エステヴェ キミカ, エス.エー. | Preparation method of sodium salt of esomeprazole sodium |
CN102329302A (en) * | 2011-10-22 | 2012-01-25 | 刘强 | Method for preparing esomeprazole and salts thereof |
CN102432412A (en) * | 2011-10-28 | 2012-05-02 | 成都欣捷高新技术开发有限公司 | Preparation method of chiral sulphoxide proton pump inhibitor or pharmaceutically-acceptable salt thereof |
US9932305B2 (en) | 2012-01-10 | 2018-04-03 | Studiengesellschaft Kohle Mbh | Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst |
WO2013104605A3 (en) * | 2012-01-10 | 2013-09-26 | Studiengesellschaft Kohle Mbh | Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst |
CN102603621A (en) * | 2012-02-07 | 2012-07-25 | 成都苑东药业有限公司 | Novel chiral sulfoxide compound and method for preparing esomeprazole by using novel chiral sulfoxide compound |
CN102924434B (en) * | 2012-10-18 | 2014-06-18 | 江苏诚信制药有限公司 | Dexrabeprazole sodium monohydrate crystal form and preparation method thereof |
CN102924434A (en) * | 2012-10-18 | 2013-02-13 | 江苏诚信制药有限公司 | Dexrabeprazole sodium monohydrate crystal form and preparation method thereof |
CN103772355A (en) * | 2012-10-25 | 2014-05-07 | 天津汉瑞药业有限公司 | Rabeprazole sodium compound |
CN105294652A (en) * | 2012-10-25 | 2016-02-03 | 天津汉瑞药业有限公司 | Rabeprazole sodium compound |
CN103772355B (en) * | 2012-10-25 | 2016-03-02 | 天津汉瑞药业有限公司 | Sodium rabeprazole compound |
CN103113350A (en) * | 2013-02-27 | 2013-05-22 | 安徽省新星药物开发有限责任公司 | Novel crystal form of R-rabeprazole sodium hydrate, preparation method and application thereof |
CN104327049A (en) * | 2014-09-27 | 2015-02-04 | 湖南五洲通药业有限责任公司 | Preparation method of right-handed rabeprazole sodium monohydrate crystal |
Also Published As
Publication number | Publication date |
---|---|
EA201070021A1 (en) | 2010-06-30 |
KR20100020035A (en) | 2010-02-19 |
BRPI0813191B1 (en) | 2021-09-08 |
KR101432866B1 (en) | 2014-08-26 |
BRPI0813191A2 (en) | 2014-12-23 |
ZA200908887B (en) | 2011-02-23 |
EA016297B1 (en) | 2012-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008152462A1 (en) | A process of sulfoxidation of biologically active compounds | |
US8404853B2 (en) | Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds | |
RU2144031C1 (en) | Method of optical purification of enantimer-enriched benzimidazole derivatives | |
JP3795917B2 (en) | Synthesis of substituted sulfoxides | |
CN101133049B (en) | Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1'-binaphthalene-2, 2'diol | |
WO2003089408A2 (en) | Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts | |
CN102584792A (en) | Method for preparing high-purity esomeprazole | |
CN101429192A (en) | Novel method for producing chiral sulfoxide derivant | |
CN100347167C (en) | Process for producing substituted 2-(2-pyridylmethye)sulfinye-1H-benzinmidazoles | |
BRPI0414298B1 (en) | process for preparing a sulfoxide compound | |
JP2001508466A (en) | New manufacturing method | |
EP1718636B1 (en) | New compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation | |
CN103113351A (en) | Method for preparing optically pure chiral sulfoxide compound | |
JP2005530795A (en) | Method for producing bicalutamide | |
CN101323609B (en) | Method for synthesizing high antipode content benzimidazole derivative by unsymmetrical oxidizing thioether into sulphoxide | |
TW202200546A (en) | Preparation method of aromatic ether compound | |
WO2011120475A1 (en) | A method of manufacturing (s)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2- pyrimidinyl)methyl]sulfinyl]-1h-benzimidazole using a chiral complex with mandelic acid | |
JP6325178B2 (en) | Improved method of optical purification of esomeprazole | |
KR20100067886A (en) | Method of preparing (r)-(+)-lansoprazole and intermediate used therein | |
WO2010150276A2 (en) | Process for preparing sulphoxide compounds | |
CZ2009777A3 (en) | Process for preparing (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and salts thereof u | |
JP2002138086A (en) | Manufacturing method of alkyloxyaminofuranone derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08762764 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20107000731 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201070021 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201000306 Country of ref document: UA |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08762764 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: PI0813191 Country of ref document: BR Kind code of ref document: A2 Effective date: 20091214 |